Last reviewed · How we verify
NCT07269314
Introduction of Polymerase Chain Reaction (PCR) in Microbiology and Parasitology
trial in Malaria, Pneumocystis, Leishmania in 200 participants. Currently enrolling.
1 September 2026
Quick facts
| Lead sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 September 2023 |
| Primary completion | 1 September 2026 |
| Estimated completion | 1 December 2026 |
| Sites | 1 location across Italy |
Conditions studied
- Malaria, Pneumocystis, Leishmania — all drugs for Malaria, Pneumocystis, Leishmania →
Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Who can join
Eligibility, any sex, with Malaria, Pneumocystis, Leishmania. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal is to develop molecular systems to support or replace in microscopic characterization and in vitro tests with molecular biology systems capable of improving performance in parasitology tests. In particular, we will analyze the main pathogens: several Leishmania species (Old and New World Leishmania species), the five Plasmodium species of human interest (falciparum, oval, vivax, malariae and knowlesi) and Pneumocistys jiroveci, using molecular methods based on the speed, specificity and sensitivity necessary for their diagnosis. Furthermore, we want to provide specific elements for the typing of the species. Our aim is to improve diagnostic and specie classification methods by using PCR in microbiology and parasitology, to evaluate its impact on diagnosis. We would evaluate the impact of this method in terms of timing, sensitivity and specificity of diagnosis. We would also explore future possibilities on quantification techniques, in order to support the clinician to evaluate the efficacy of therapy during the follow-up. Furthermore, we would evaluate these methods in terms of cost effectiveness towards classical direct methods, which are now operator-dependent.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07269314
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Fondazione IRCCS Policlinico San Matteo di Pavia trials
Trials by the same sponsor.
- NCT07534007 — Comprehensive Characterization of Immune Response Induced by Adjuvanted Glycoprotein E (gE)-Based Recombinant VAccine Zo · recruiting
- NCT07494344 — Italian Retrospective/Prospective Observational Study on Prosthetic Surgery in Patients With Congenital Coagulation Dise · recruiting
- NCT07356583 — Neonatal Enterovirus Infections in Italy: Virological Characterization, Genomic and Clinical-epidemiological Insights on · recruiting
- NCT07435207 — Thrombotic RIsk FActors in AL-goneurodystrophy · enrolling by invitation
- NCT07263802 — Effect of a Food Supplement on Glycemic Parameters in Patients With Impaired Glucose Metabolism · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07269314 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondazione IRCCS Policlinico San Matteo di Pavia
- Last refreshed: 8 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07269314.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing